What question did this study set out to answer?

To assess the 48-week efficacy and safety of switching to a two-drug regimen of dolutegravir/lamivudine versus continuing a standard three- or four-drug regimen in adults with virologically suppressed HIV-1.

March 1, 2022Clinical Infectious DiseasesOpen Access

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

View Full Paper

Ask AI

Bookmark

Authors

JLJosep M. LlibreBadalona Serveis Assistencials CBCarlos BritesUniversidade Federal da Bahia CCChien‐Yu ChengMinistry of Health and Welfare

Discussion

Member takes

Implication

Randomized noninferiority trial evaluates dolutegravir/lamivudine versus multi-drug regimens in adults with HIV-1, indicating two-drug therapy maintains viral control.

Key Points

To assess the 48-week efficacy and safety of switching to a two-drug regimen of dolutegravir/lamivudine versus continuing a standard three- or four-drug regimen in adults with virologically suppressed HIV-1.
Phase 3, randomized, noninferiority clinical trial (SALSA trial, NCT04021290) in adults living with HIV-1 who had achieved virologic suppression.
Participants switched to a two-drug regimen of dolutegravir/lamivudine or continued their baseline three- or four-drug antiretroviral therapy over a 48-week follow-up period.
The trial evaluated maintenance of virologic suppression at week 48 between the two-drug switch strategy and continued multi-drug therapy.
Primary noninferiority outcomes and specific event rates were not provided in the source text.

Cite This Study

Llibre et al. (2022) studied this question.

synapsesocial.com/papers/69d93c7bed2e131d3c684072 https://doi.org/10.1093/cid/ciac130

View Full Paper

Ask AI

Bookmark

Implication

Randomized noninferiority trial evaluates dolutegravir/lamivudine versus multi-drug regimens in adults with HIV-1, indicating two-drug therapy maintains viral control.

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider